American Tower vs Crown Castle
AMT and CCI side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMT and CCI compare
American Tower is the larger company, worth 2.3 times as much as Crown Castle ($87.5B against $37.7B).
On earnings, American Tower is cheaper: it trades at 25.8× trailing earnings, against 45.0× for Crown Castle.
American Tower grew revenue faster over the last twelve months (6.6% versus −4.6% for Crown Castle).
Both pay dividends: American Tower yields 3.8% and Crown Castle 4.8%.
American Tower scores higher on the StockData Score (7 against 6 for Crown Castle), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMT | CCI |
|---|---|---|
| Size and price | ||
| Market cap | $87.5B | $37.7B |
| Share price | $187.78 | $88.69 |
| Change, 1 year | 4.9% | −3.9% |
| Change, 5 years | −32.4% | −50.8% |
| Beta (5Y) | 0.59 | 0.57 |
| Employees | 4,866 | 4,000 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 0 | 0 |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 25.8× (better) | 45.0× |
| P/S | 8.0× (better) | 9.1× |
| P/B | 23.5× | – |
| EV/EBITDA | 18.6× (better) | 20.6× |
| P/FCF | 22.1× | 15.7× (better) |
| PEG | 2.11 | – |
| FCF yield | 4.5% | 6.4% (better) |
| Fair value | $184.63 | $66.32 |
| Margin of safety | −1.7% (better) | −33.7% |
| Growth | ||
| Revenue growth (TTM) | 6.6% (better) | −4.6% |
| Revenue growth, 5Y average | 5.8% (better) | −6.1% |
| EPS growth (TTM) | 164% | – |
| EPS growth, 5Y average | 7.3% (better) | −15.5% |
| Profitability | ||
| Gross margin | – | 97.5% |
| Operating margin | 44.8% | 47.7% (better) |
| Net margin | – | 20.7% |
| FCF margin | 36.2% | 57.8% (better) |
| Return on invested capital | 11.2% | – |
| Financial health | ||
| Debt / equity | 10.00 | – |
| Net debt / EBITDA | 5.08 (better) | 6.46 |
| Interest coverage | 3.5× (better) | 2.1× |
| Current ratio | 0.35 | 0.52 (better) |
| Altman Z-score | 1.20 (better) | −0.03 |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Dividend yield | 3.8% | 4.8% (better) |
| Payout ratio | – | −267% |
| Years of dividend growth | 3 (better) | 0 |
| Dividend growth, 5Y average | – | −0.74% |
| Buyback yield | – | 2.6% |
| Shareholder yield | 3.8% | 7.4% (better) |
| Ownership | ||
| Held by institutions | 94.5% | 99.4% |
| Held by insiders | 0.09% | 0.11% |
| Insider net buying, 12 months | −$22.2M | −$854K (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 1.6% | 2.2% |
Go deeper
- AMT stock overview
- AMT income statement
- AMT valuation and score
- CCI stock overview
- CCI income statement
- CCI valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.